Results
XPC PAT +/+ genotype was associated with elevated risk of BC (
p = 0.021, OR = 2.49).
XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (
p = 0.041, OR = 2.52). Haplotype analysis revealed that variant genotypes C of
XPC Lys939Gln and + of PAT, C+ were significantly associated with risk of BC (
p = 0.004, OR = 1.70). The CC genotype of Lys939Gln was associated with high risk for recurrence in BCG-treated patients (HR = 3.21,
p = 0.036) thus, showing reduced recurrence-free survival (AC + CC/AA = 36/60 months; log rank
p = 0.045).